Navigation Links
Erectile Dysfunction More Common in Men Who Regularly Take Prescription Painkillers
Date:5/15/2013

ch and Oregon Health & Science University; David Smith , RPh, PhD,  Eric S. Johnson , PhD, Xiuhai Yang , MS, and Amanda Petrik , MS, from the Kaiser Permanente Center for Health Research; Carrie J. Tillotson , MPH, from Oregon Health & Science University; Benjamin J. Morasco , PhD, and Steven K. Dobscha , MD, from Oregon Health & Science University and the Veterans Administration Medical Center in Portland, Ore.; and Marilee Donovan RN , PhD, from Kaiser Permanente Northwest in Portland, Ore.

About the Kaiser Permanente Center for Health Research
The Kaiser Permanente Center for Health Research, founded in 1964, is a nonprofit research institution dedicated to advancing knowledge to improve health. It has research sites in Portland, Ore., Honolulu, and Atlanta. http://www.kpchr.org

About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and nonprofit health plans. Founded in 1945, our mission is to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve 9.1 million members in nine states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention,
'/>"/>

SOURCE Kaiser Permanente
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Increased Dosage of Needle-Free Erectile Dysfunction Medication TriMix-gel Now Available through KRS Global Biotechnology
2. Fight Erectile Dysfunction the Safe and Healthy Way with Function for Men
3. Testosterone Therapy: A Misguided Approach to Erectile Dysfunction (ED)
4. A Novel Oral Anticoagulant is Planned to be Developed for Patients with Prosthetic Heart Valves or Chronic Renal Dysfunction
5. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
6. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
7. Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
9. MEI Pharma Announces $15.2 Million Registered Offering Of Common Stock
10. Vasomedical Announces Share Repurchase Program of up to $1.5 Million in Common Stock
11. Safe in Common to Exhibit at 61st Annual National Student Nurses Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... PALO ALTO, Calif., March 8, 2011 Jazz Pharmaceuticals, Inc. ... will be providing a business update at two upcoming investor ... financial officer, will provide an update at the ROTH 23rd ... Monday, March 14, 2011 at 4:30 p.m. Pacific Time ...
... Warner Chilcott plc (Nasdaq: WCRX ) ... its ordinary shares by certain selling shareholders. The selling ... Morgan Partners (advised by CCMP Capital) and Thomas H. ... management. The offering is being conducted as a public ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4
(Date:4/17/2014)... The presence of chronic inflammation in benign prostate ... cancer, and this association was found even in ... to a study published in Cancer Epidemiology, ... American Association for Cancer Research. , An analysis ... of the placebo arm of the Prostate Cancer ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2
... ... implicate the purchaser in any lawsuit or cause such purchasers to be a party ... ... highly respected developer and manufacturer of proprietary skin care formulations, who also is the ...
... ... latest version of its revolutionary cost-cutting software. Newly developed upgrades to iCodeRx, iDocs, and ... processes, while providing the highest security possible to patient information. , ... Virginia Beach, VA (PRWEB) - DOMA ...
... ... a new agreement with B. E. Smith for Executive Leadership Solutions. , ... Lenexa, KS (Vocus) September 24, ... agreement with B. E. Smith for Executive Leadership Solutions., , ,Effective immediately, through August ...
... trials, advanced cancers shrunk rapidly, researchers say , THURSDAY, ... advanced melanoma promotes rapid shrinking of tumors, according to ... includes patients with the cancer-causing mutation of the BRAF ... melanomas and 5 percent of colorectal cancers. , The ...
... say , THURSDAY, Sept. 24 (HealthDay News) -- Surgery ... carpal tunnel syndrome who don,t have severe nerve damage ... 44 patients who had surgery and 52 patients who ... A year after treatment, the patients, hand function was ...
... drugs increase the possibility of septal malformation, researchers find ... who take certain antidepressants during the first three months ... giving birth to babies with heart defects. , Septal ... right side of the heart from the left -- ...
Cached Medicine News:Health News:Purchase PHYTO-C Skincare Will Not Implicate in the Lawsuit 2Health News:DOMA Transforms Healthcare IT with Increased Security While Reducing Cost -- iCodeRx/iDocs/iCharts 6.0 Debuts at AHIMA National Convention 2Health News:DOMA Transforms Healthcare IT with Increased Security While Reducing Cost -- iCodeRx/iDocs/iCharts 6.0 Debuts at AHIMA National Convention 3Health News:Members to Benefit from New Agreement between Amerinet and B. E. Smith 2Health News:New Treatment May Beat Melanoma 2Health News:New Treatment May Beat Melanoma 3Health News:Surgery Best for Carpal Tunnel Syndrome 2Health News:Surgery Best for Carpal Tunnel Syndrome 3Health News:Antidepressants Linked to Heart Defects in Newborns 2Health News:Antidepressants Linked to Heart Defects in Newborns 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: